corresponding period of last year. EBITDA improved by 54 per cent to Rs.172 crore from Rs.112 crore. EBIDTA margins improved to 19.8 per cent from 14.8 per cent. Its standalone net sales increased by 14.5 per cent to Rs.859 crore from Rs.750 crore. With smart improvement in profits, EPS went up to Rs.8.37 from Rs.3.28 in the last period.
Ipca's domestic sales from formulations went up by 12 per cent to Rs.383 crore from Rs.343 crore and its formulation exports increased by 17 per cent to Rs.273 crore from Rs.233 crore. APIs sales moved up by 16 per cent to Rs.192 crore from Rs.165 crore. Out of this, Domestic APIs sales increased by 59 per cent to Rs.59 crore from Rs.37 crore and APIs exports increased by 4 per cent to Rs.133 crore from Rs.128 crore.
During the first nine months ended December 2017, Ipca's standalone net sales declined by 2.1 per cent to Rs.2,436 crore from Rs.2,489 crore. However its net profit increased by 26.4 per cent to Rs.181 crore from Rs.144 crore. Its domestic formulation sales declined by one per cent to Rs.1,103 crore from Rs.1,112 crore and formulation export declined by 4 per cent to Rs.743 crore from Rs.772 crore. However, domestic sales of APIs increased by 23 per cent to Rs.143 crore from Rs.116 crore. However, APIs exports declined by 6 per cent to Rs.414 crore from Rs.441 crore. EBIDTA margins declined to 14.6 per cent from 15.1 per cent in last period.